logo
In This Issue/Research Watch/News-in-Brief/News from the IASLC Tobacco Control Committee
The Obesity Paradox—What Does It Mean for Lung Cancer Surgery?
The Financial Implications of Lung Cancer Screening: Is It Worth It?
MET ex14-Positive NSCLC: Time to Take the Therapy to the Target to Aim for a Cure?
Scientific Advances in Thoracic Oncology 2016
The Cost-Effectiveness of High-Risk Lung Cancer Screening and Drivers of Program Efficiency
Cost-Effectiveness of a Bronchial Genomic Classifier for the Diagnostic Evaluation of Lung Cancer
MET Exon 14 Skipping Mutations in Lung Adenocarcinoma: Clinicopathologic Implications and Prognostic Values
EGFR Mutation Analysis for Prospective Patient Selection in Two Phase II Registration Studies of Osimertinib
Gene Expression Profiling of Large Cell Lung Cancer Links Transcriptional Phenotypes to the New Histological WHO 2015 Classification
Interleukin-17A Promotes Lung Tumor Progression through Neutrophil Attraction to Tumor Sites and Mediating Resistance to PD-1 Blockade
The Influence of Body Mass Index on Overall Survival Following Surgical Resection of Non–Small Cell Lung Cancer
Lung Adenocarcinoma Manifesting as Pure Ground-Glass Nodules: Correlating CT Size, Volume, Density, and Roundness with Histopathologic Invasion and Size
Phase I Trial of Cediranib in Combination with Cisplatin and Pemetrexed in Chemonaive Patients with Unresectable Malignant Pleural Mesothelioma (SWOG S0905)
A Novel BRCA1-Associated Protein-1 Isoform Affects Response of Mesothelioma Cells to Drugs Impairing BRCA1-Mediated DNA Repair
Lung Metastases from Esophageal Granular Cell Tumor: An Undoubted Criterion for Malignancy
Robert Comis, MD, The Passing of a “Lung Man”
Erratum
Antineutrophil Cytoplasmic Antibody–Associated Rapid Progressive Glomerulonephritis after Pembrolizumab Treatment in Thymic Epithelial Tumor: A Case Report
Durable Response to Afatinib in Lung Adenocarcinoma Harboring NRG1 Gene Fusions
Pericardial Tamponade Caused by a Hypersensitivity Response to Tuberculosis Reactivation after Anti–PD-1 Treatment in a Patient with Advanced Pulmonary Adenocarcinoma
Numb Chin Syndrome: An Ominous Sign of Lung Cancer
FISH Analysis of Crizotinib Target Genes ROS1/ALK/MET in Malignant Mesothelioma
Osimertinib-Induced Interstitial Lung Disease Presenting as Eosinophilic Pneumonia
Pulmonary Adenocarcinoma with Enteric Differentiation Presenting with Bronchorrhea
Chronic Cholestasis with Dilation of Intrahepatic Bile Duct Related to Administration of Ceritinib
Reframing the Concept of “No Treatment” in Advanced NSCLC
Response to “Reframing the Concept of ‘No Treatment’ in Advanced NSCLC”
Questions Regarding “ CD74-ROS1 Fusion in NSCLC Detected by Hybrid Capture-Based Tissue Genomic Profiling and ctDNA Assays”
A Case of Heart Failure after Treatment with Anti–PD-1 Antibody Followed by Adoptive Transfer of Cytokine-Activated Killer Cells in a Recurrent Lung Cancer Patient
Smoking History Predicts Sensitivity to PARP Inhibitor Veliparib in Patients with Advanced Non–Small Cell Lung Cancer: Methodological Issues
Concern: Improving the Accuracy of Mesothelioma Diagnosis in China
Improving the Accuracy of Mesothelioma Diagnosis in China